Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo …

KA Papp, R Kaufmann, D Thaçi, C Hu… - Journal of the …, 2013 - Wiley Online Library
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo …

KA Papp, R Kaufmann, D Thaçi, C Hu… - Journal of the European …, 2013 - infona.pl
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo …

KA Papp, R Kaufmann, D Thaçi, C Hu… - Journal of the …, 2013 - search.ebscohost.com
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production …

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo …

KA Papp, R Kaufmann, D Thaçi… - Journal of the …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production …

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: Results from a phase II, multicenter, randomized, double-blind, placebo …

KA Papp, R Kaufmann, D Thaçi, C Hu… - Journal of the …, 2013 - research.uni-luebeck.de
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production …

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo …

KA Papp, R Kaufmann, D Thaçi, C Hu… - Journal of the …, 2012 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p>< jats: bold> Background</jats: bold>
Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly …

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo …

KA Papp, R Kaufmann, D Thaçi, C Hu… - Journal of the …, 2012 - europepmc.org
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results
from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group …

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: Results from a phase II, multicenter, randomized, double-blind, placebo …

KA Papp, R Kaufmann, D Thaçi, C Hu… - Journal of the …, 2013 - research.uni-luebeck.de
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production …